| 52nd week of 2021 patent applcation highlights part 27 |
| Patent application number | Title | Published |
|---|
| 20210403470 | NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS - The present invention relates to novel methods of preparation of substituted pyridines and the compounds produced therefrom. In particular, the present invention provides efficient methods for the construction of diversely substituted pyridines, with varying substitution patterns under simple and metal-free conditions with high atom- and pot-economy and excellent functional group tolerance, and which are useful for the synthesis of natural products. | 2021-12-30 |
| 20210403471 | FOLATE SALTS - The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol. | 2021-12-30 |
| 20210403472 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) - The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described. | 2021-12-30 |
| 20210403473 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals. In some embodiments, the present disclosure provides a compound of Formula (A) or a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer. | 2021-12-30 |
| 20210403474 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF - Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system. | 2021-12-30 |
| 20210403475 | NOVEL SELECTIVE PI3K DELTA INHIBITORS - The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them. | 2021-12-30 |
| 20210403476 | ION CHANNEL MODULATORS - The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein. | 2021-12-30 |
| 20210403477 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof - Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents. | 2021-12-30 |
| 20210403478 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS - Compounds of formula I | 2021-12-30 |
| 20210403479 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION - The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R | 2021-12-30 |
| 20210403480 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS - Novel selective estrogen receptor degraders (SERDs) according to the formula: | 2021-12-30 |
| 20210403481 | ORGANIC LIGHT-EMITTING MATERIAL AND MANUFACTURING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DEVICE - An organic light-emitting material and the manufacturing method thereof, and an organic light-emitting device are disclosed. The organic light-emitting material includes a benzophenanthrene derivative, which has good planarity and strong visible π-π* absorption ability and has a high quantum yield of blue light-emitting capability as well. Therefore, a benzophenanthrene derivative having a large π-conjugated system has high-efficiency electron transporting properties, and its high electron-withdrawing group increases electron mobility rate and effectively improve the light-emitting efficiency of the organic light emitting device. | 2021-12-30 |
| 20210403482 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS - The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds. | 2021-12-30 |
| 20210403483 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES - Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: | 2021-12-30 |
| 20210403484 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS - The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention. | 2021-12-30 |
| 20210403485 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR - The present invention discloses a compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to use thereof in preparing a medicament for treating solid tumor-related diseases. | 2021-12-30 |
| 20210403486 | SELENOPHENOCHROMENE HYDROXAMIC ACIDS, PREPARATION AND USE AS ANGIOGENESIS INHIBITORS - The present invention relates to a novel selenophenochromene hydroxamic acids as angiogenesis inhibitors, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment or prevention of various diseases and disorders by administration of such substances. | 2021-12-30 |
| 20210403487 | NEW FORMS OF PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES, ITS FORMULATION AND ITS PROCESS OF MAKING - The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds. | 2021-12-30 |
| 20210403488 | COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM INCLUDING SAME, BACKLIGHT UNIT, AND DISPLAY DEVICE - The present specification relates to a color conversion composition including a compound represented by Chemical Formula 1 and a compound represented by Chemical Formula 2 in a molar ratio of 1:1 to 5:1, and a color conversion film, a backlight unit and a display apparatus including the same. | 2021-12-30 |
| 20210403489 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME - A compound represented by Formula 1 and an organic light emitting device including the same, and the compound providing lower driving voltage, improved light efficiency, and improved service life characteristics of the organic light emitting device. | 2021-12-30 |
| 20210403490 | NOVEL BORON COMPOUND, AND ORGANIC LIGHT-EMITTING DIODE COMPRISING SAME - The present disclosure relates to a boron compound useful in an organic light-emitting diode and an organic light-emitting diode comprising same and, more particularly, to a boron compound represented by [Chemical Formula A], wherein [Chemical Formula A] and [Chemical Formula C] are as defined in the description. | 2021-12-30 |
| 20210403491 | CESIUM OXALATE PRODUCTION FROM CESIUM CARBONATE - Processes for producing a disubstituted oxalate are disclosed. The process includes contacting a mixture of cesium salt and gamma alumina with one or more alcohols and carbon dioxide (CO | 2021-12-30 |
| 20210403492 | GROUP 5 METAL COMPOUND FOR THIN FILM DEPOSITION AND METHOD OF FORMING GROUP 5 METAL-CONTAINING THIN FILM USING SAME - A group 5 metal compound according to an embodiment of the present disclosure is represented by any one of the following and : | 2021-12-30 |
| 20210403493 | USE OF TWO-TAIL LONG-CHAIN ANIONIC SURFACTANTS IN AQUEOUS POLYURETHANE DISPERSIONS - The use of two-tail long-chain anionic surfactants as additives in aqueous polymer dispersions for production of porous polymer coatings, preferably for production of porous polyurethane coatings, is described. | 2021-12-30 |
| 20210403494 | ELECTROLUMINESCENT MATERIAL, METHOD FOR MANUFACTURING SAME, AND LIGHT EMITTING DEVICE - The present application provides an electroluminescent material, a method for manufacturing the electroluminescent material, and a light emitting device, by employing an anthracene group and a triphenylphosphine oxide group, applying the molecule containing the anthracene group showing an excellent light emitting characteristic and two electron-deficient triphenylphosphine oxide groups located at the 6-position and 13-position of the anthracene group, an electroluminescent material, a method for manufacturing the electroluminescent material and a light emitting device with a blue light emitted and high luminous efficiency are achieved. | 2021-12-30 |
| 20210403495 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) - The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof. Also provided are methods (or uses) and kits involving the compounds or pharmaceutically acceptable compositions containing them for treating or preventing a disease (e.g., a proliferative disease such as cancer) in a subject. Administration of a compound or pharmaceutical composition described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, induce apoptosis in tumor cells in the subject. | 2021-12-30 |
| 20210403496 | PHOSPHORESCENT ORGANIC METAL COMPLEX AND USE THEREOF - Provided are a phosphorescent organometallic complex and a use thereof. The metal complex has a ligand with a structure represented by Formula 1 and may be used as a light-emitting material in an electroluminescent device. These novel metal complexes can not only maintain high device efficiency and low voltage in electroluminescent devices but also allow these devices to have narrower half-peak width so as to greatly improve color saturation of light emitted by these devices, thereby providing better device performance. Further provided are an electroluminescent device and a compound formulation. | 2021-12-30 |
| 20210403497 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS - Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I. | 2021-12-30 |
| 20210403498 | PHYTOCHEMICAL-FRUCTOOLIGOSACCHARIDE CONJUGATE, METHOD FOR PRODUCING SAME, AND USE THEREOF - The present invention provides a novel phytochemical-fructooligosaccharide conjugate having a structure in which a phytochemical in the form of phenolic acid is conjugated to a portion of saccharides constituting a fructooligosaccharide backbone. Compared to corresponding phenolic acid phytochemicals, the novel phytochemical-fructooligosaccharide conjugate according to the present invention is hardly decomposed under oral-gastrointestinal transit conditions such that most of the phytochemical-fructooligosaccharide conjugate may reach the large intestine. Thus, the novel phytochemical-fructooligosaccharide conjugate has good bioavailability in the large intestine when orally administered. In particular, a ferulic acid-fructooligosaccharide conjugate according to the present invention has an excellent colorectal cancer cell-selective killing effect as compared to commercial colorectal cancer treatment drugs, and may thus be used as a food or pharmaceutical material useful for preventing, alleviating, or treating colorectal cancer. | 2021-12-30 |
| 20210403499 | CARBOHYDRATE-BASED SURFACTANTS - The present invention provides carbohydrate-based surfactants and methods for producing the same. Methods for producing carbohydrate-based surfactants include using a glycosylation promoter to link a carbohydrate or its derivative to a hydrophobic compound. | 2021-12-30 |
| 20210403500 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP - Embodiments of the present disclosure relate to nucleotide and nucleoside molecules with acetal 3′-OH blocking groups. Also provided herein are methods to prepare such nucleotide and nucleoside molecules, and the uses of fully functionalized nucleotides containing the 3′ acetal blocking group for sequencing applications. | 2021-12-30 |
| 20210403501 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 - The disclosure provides compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A | 2021-12-30 |
| 20210403502 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF - Described herein are steroids of Formula (I): | 2021-12-30 |
| 20210403503 | METHOD FOR CONJUGATION OF BIOMOLECULES AND NEW USE OF GOLD DONOR FOR BIOMOLECULAR COMPLEX FORMATION - The subject matter of the invention is a method for conjugation of free thiol group(s) containing biomolecules, leading to the biomolecular complex formation, comprising a reaction to connect biomolecules using a gold-donor agent in which a —S—Au—S— bond is formed, characterised in that a gold-donor agent is halogen(triarylphosphine)gold (I). The subject matter of the invention is also the use of halogen(triarylphosphine)gold (I) molecules as the gold-donor agent in the method of biomolecular complex formation. | 2021-12-30 |
| 20210403504 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 2021-12-30 |
| 20210403505 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS - The present invention provides compounds which are selective kappa-opioid receptor agonist, method of preparation of these compounds, compositions that comprise these compounds, and methods for treating kappa-opiod receptor agonist related medical disorders | 2021-12-30 |
| 20210403506 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME - Disclosed in the present invention are a peptide compound, an application thereof, and a composition containing the same. Provided in the present invention are a peptide compound represented by formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a solvate thereof, a crystal form thereof, or a prodrug thereof. The compound has good stability and good activity. | 2021-12-30 |
| 20210403507 | PEPTIDE PROBE FOR RECOGNITION OF G-QUADRUPLEX AND USE THEREOF IN DETECTION OF G-QUADRUPLEX IN CELL - A polypeptide probe, including: from two to four G4-binding domains, and one or more linkers disposed between every two G4-binding domains. Each G4-binding domain includes a specific motif including a sequence of amino acids | 2021-12-30 |
| 20210403508 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME - The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step. | 2021-12-30 |
| 20210403509 | S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USE - Described are S-layer fusion proteins comprising a self-assembling domain of a S-layer protein and a viral spike protein or a fragment thereof, a pharmaceutical composition (such as a vaccine) comprising the S-layer fusion protein, and method of immunizing a patient in need thereof comprising administering the vaccine. | 2021-12-30 |
| 20210403510 | MODIFIED CAPSID PROTEINS FOR ENHANCED DELIVERY OF PARVOVIRUS VECTORS - This invention relates to modified parvovirus capsid proteins with enhanced transduction efficiency, viral vectors comprising the same, and methods of using the same for delivery of nucleic acids to a cell or a subject. | 2021-12-30 |
| 20210403511 | NUCLEIC ACIDS AND METHODS FOR GENOME EDITING - Presented herein, in certain embodiments, are nucleic acids and compositions for use in targeted gene editing. | 2021-12-30 |
| 20210403512 | ANTIMICROBIAL TYPE-II BACTERIOCINS - Computational systems and methods are described for identifying new type-II bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-II bacteriocin peptides are tested experimentally and show potent microbiocidal activities. | 2021-12-30 |
| 20210403513 | BUDDING YEAST WITH HUMAN CHROMATIN - Yeast having modified chromosomes are provided. The chromosomes are modified such that at least one of yeast histones H3, H4, H2A or H2B are fully or partially replaced by their human histone counterparts H3, H4, H2A or H2B, respectively. Histone amino acid substitutions are included. Cell fusions with the yeast having the modified chromosomes and non-yeast cells are provided. Methods for screening test agents using the yeast are also provided. Yeast with a mutated yeast DAD1 gene, the mutated DAD1 gene encoding an E50D mutation in yeast DAD1 protein, are provided, and provide a useful genetic background for making the yeast with partially or fully replaced histone(s). | 2021-12-30 |
| 20210403514 | COMPOSITIONS AND METHODS FOR TREATMENT OF BONE ASSOCIATED DISEASES - Mutant M-CSF protein, comprising α | 2021-12-30 |
| 20210403515 | FUSION-PROTEINS BASED ON HUMAN FERRITIN AND PROTEASE-CLEAVABLE PEPTIDES AND THEIR USE AS CHEMOTHERAPEUTICS CARRIERS - A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof. A fusion protein based on the heavy chain of human ferritin is de-scribed, which includes at the N terminus of the protein at least one metalloproteinase cleavage sequence and a modified PAS polypeptide that acts as a masking polymer that in-creases the protein drug stability, as well as a nanoparticle composed of multiple monomers of said fusion protein, a nucleic acid encoding for said fusion protein, and diagnostic and therapeutic applications thereof. | 2021-12-30 |
| 20210403516 | ANTI-CANCER FUSION POLYPEPTIDE - The disclosure provides a fusion polypeptide specific for both CD137 and GPC3, which fusion polypeptide can be useful for directing CD137 clustering and activation to GPC3-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides. | 2021-12-30 |
| 20210403517 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF - D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications. | 2021-12-30 |
| 20210403518 | BISTABLE TYPE II OPSINS AND USES THEREOF - Bistable type II opsins are provided. Accordingly, there is provided a polypeptide comprising a bistable type II opsin and a heterologous ER export signal and/or membrane trafficking signal. Also provided are polynucleotides encoding same, cells expressing same and methods of use thereof. | 2021-12-30 |
| 20210403519 | METHODS AND COMPOSITIONS TO INDUCE OR SUPPRESS IMMUNE RESPONSES THROUGH THE USE OF MEMBRANE BOUND COMPLEMENT SPLIT PRODUCTS - Methods and compositions for stimulating or inhibiting antigen-specific immune responses using surface-anchored complement split products are described heron. | 2021-12-30 |
| 20210403520 | CELL PENETRATING PEPTIDES THAT INHIBIT IRF5 NUCLEAR LOCALIZATION - Inhibitors of interferon regulatory factor 5 (IRF5) nuclear localization and methods of using the inhibitors to treat autoimmune diseases such as systemic lupus erythematosus (SLE) are described. | 2021-12-30 |
| 20210403521 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING KIDNEY INJURY - One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury. | 2021-12-30 |
| 20210403522 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE - This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy. | 2021-12-30 |
| 20210403523 | COMPOSITIONS AND METHODS FOR TREATMENT OF FUNGAL INFECTIONS - Peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensins. | 2021-12-30 |
| 20210403524 | ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF - The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. | 2021-12-30 |
| 20210403525 | TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF - The present invention relates, in part, to chimeric proteins comprising mutant interferon-γ and their use as therapeutic agents. | 2021-12-30 |
| 20210403526 | TMEM100 PEPTIDES AND VARIANTS THEREOF AND THEIR USE IN TREATING OR PREVENTING DISEASES OR CONDITIONS - The present invention features compositions of Tmem100 peptides and variants thereof, and their use in treating or preventing diseases or conditions. | 2021-12-30 |
| 20210403527 | NY-ESO-1 T CELL RECEPTORS AND METHODS OF USE THEREOF - The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) peptides, as well as therapeutic and diagnostic methods of using those isolated TCRs. | 2021-12-30 |
| 20210403528 | Novel T-Cell Receptor and Ligand - The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR. | 2021-12-30 |
| 20210403529 | TCR-ENRICHED CLONOTYPE, ACQUISITION METHOD AND USE THEREOF - Disclosed are TCR-enriched clonotypes, and an acquisition method and use thereof. Amino acid sequences of the TCR-enriched clonotypes are: CAANRGSGYSTLTF_CSARGERGEKLFF, CASSSGGSYIPTF_CASSLAGGHETQYF, CAVNSYNTDKLIF_CATSREEDNTYEQYF, CAVGGNEKLTF_CASSQGTGRSSPLHF, or CAASAVGGAQKLVF_CATSRGTLYGYTF, respectively. The TCR-enriched clonotypes can be used for vaccine development. | 2021-12-30 |
| 20210403530 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-30 |
| 20210403531 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-30 |
| 20210403532 | IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF - The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease. | 2021-12-30 |
| 20210403533 | IL-IR-I BINDING POLYPEPTIDE - The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX | 2021-12-30 |
| 20210403534 | IL1-R1 DERIVED INHIBITOR OF IL-1b AND USE THEREOF - A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1β. In certain aspects, the disclosed composition is based on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1β and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals. | 2021-12-30 |
| 20210403535 | NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF - The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition. | 2021-12-30 |
| 20210403536 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS - This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal. | 2021-12-30 |
| 20210403537 | BINDING AGENTS TO PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN - Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2. | 2021-12-30 |
| 20210403538 | PAN-EBOLAVIRUS NEUTRALIZING HUMAN ANTIBODIES AND METHODS OF USE THEREFOR - The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment. | 2021-12-30 |
| 20210403539 | Dosing Regimen for Treating Influenza Virus Diseases - The present invention pertains to a dosing regimen for treating influenza virus diseases, and more specifically, to a method for treating influenza virus-related diseases through the administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. The treatment method according to the present invention enables influenza A virus-related diseases to be treated through the intravenous administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. In addition, the treatment method according to the present invention can satisfy unmet medical needs for biological therapeutic agents for influenza virus-related diseases. | 2021-12-30 |
| 20210403540 | ANTI-APOE4 ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF - The present disclosure generally relates to antigen-binding proteins (ABPs) that specifically bind to apolipoprotein E (ApoE), compositions comprising such ABPs, methods of using such ABPs, and methods of making such ABPs. In some embodiments, the ABPs provided herein bind lipidated ApoE4. In some embodiments, the lipidated ApoE4 is within a lipoprotein particle, and the ABPs therefore bind to a lipoprotein particle comprising ApoE4. Any suitable ABP may be used. In some embodiments, the ABP is an antibody. In some embodiments, the ABP is an alternative scaffold. The ABPs provided herein may be used for the prevention or treatment of any disease, condition or disorder associated with ApoE4 expression. | 2021-12-30 |
| 20210403541 | HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413 - Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof. | 2021-12-30 |
| 20210403542 | alpha-SYNUCLEIN PROTOFIBRIL-BINDING ANTIBODIES - The present disclosure is based, in part, on the discovery of antibodies that selectively targets human α-synuclein aggregates such as oligomers/protofibrils, such as BAN0805. BAN0805 has a lower tendency to bind to the undesired monomeric α-synuclein target as compared to mouse monoclonal antibody mAb47. | 2021-12-30 |
| 20210403543 | ANTIBODIES BINDING TO CITRULLINATED HISTONE 2A AND/OR 4 - The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies. The antibodies or binding fragments thereof of the invention can be used in the treatment or prevention of NET-associated pathologies such as systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, Sjögren's disease, Anti-phospholipid Syndrome, Bechet's disease, spondylitis, spondyloarthropathy, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbated asthma, allergic asthma, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, dry eye disease, uveitis, nongranulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or other NET-associated pathologies such as wound healing in diabetes, cancer, cancer metastasis, and transplant organ health in vivo or ex vivo. The invention also provides pharmaceutical compositions and methods for treating or preventing NET-associated pathologies such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, Sjögren's disease, Anti-phospholipid Syndrome, Bechet's disease, spondylitis, spondyloarthropathy, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbated asthma, allergic asthma, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, dry eye disease, uveitis, nongranulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or other NET-associated pathologies such as wound healing in diabetes, cancer, cancer metastasis, and transplant organ health in vivo or ex vivo. | 2021-12-30 |
| 20210403544 | ANTIBODIES THAT BIND TO PATHOLOGICAL TAU SPECIES AND USES THEREOF - The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau. | 2021-12-30 |
| 20210403545 | TGF-B1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF - Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein. | 2021-12-30 |
| 20210403546 | HUMANIZED AND VARIANT TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF - Antibodies, particularly humanized and variant antibodies and fragments thereof, which bind to TGF-β1 are provided, recognizing human and mouse TGF-β1, particularly that preferentially bind TGF-β1, including which do not recognize or bind TGF-β2 or TGF-β3. Humanized and variant antibodies provided are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and/or combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Particular antibodies are exemplified herein, including antibodies 13A1-2A, 13A1-2B, 13A1-2C, 13A1-2D, 13A1-2E, 13A1-2F, 13A1-2G, 13A1-2H, 13A1-2I, 13A1-2J, 13A1-AF, 13A1-AG, 13A1-AH, 13A1-BF, 13A1-BG, 13A1-BH, 13A1-CF, 13A1-CG, 13A1-CH, 13A1-DF, 13A1-DG, 13A1-DH, 13A1-EF, 13A1-EG and 13A1-EH. | 2021-12-30 |
| 20210403547 | Antibodies that bind TGF-Alpha and Epiregulin for use in the treatment of pain - The present invention provides for therapeutic use of antibodies that bind human TGF-alpha and human Epiregulin in the treatment of chronic pain, and in particular chronic osteoarthritis pain, chronic diabetic neuropathy pain, or chronic low back pain. | 2021-12-30 |
| 20210403548 | TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF - Administration of an antibody that, specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or increasing the time until restenosis occurs) in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel. | 2021-12-30 |
| 20210403549 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT OR PREVENT LIPOPROTEIN ENTRY INTO THE ENDOTHELIUM - In one aspect, the invention comprises a fusion construct comprising ALKI extracellular domain and a stability enhancing domain. In another aspect, the invention comprises an antibody that interferes with or blocks the ALKI extracellular domain binding to LDL, but does not interfere with or block the ALKI extracellular domain binding to BMP9/10. In yet another aspect, the invention comprises methods of reducing rates of LDL uptake in the endothelial cells of a patient in need thereof by administering the fusion construct or monoclonal antibodies described herein to the patient. | 2021-12-30 |
| 20210403550 | FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION - The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer. | 2021-12-30 |
| 20210403551 | APLNR Modulators and Uses Thereof - The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases. | 2021-12-30 |
| 20210403552 | ANTI-CLDN18.2 ANTIBODY AND USES THEREOF - Provided are an anti-CLDN18.2 antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding the same, an immunoconjugate, bispecific molecule, chimeric antigen receptor and pharmaceutical composition comprising the same. The antibody or antigen-binding fragment thereof is used for preventing and/or treating a tumor. | 2021-12-30 |
| 20210403553 | COMBINATION THERAPY FOR TREATMENT OF DISEASE - The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases. | 2021-12-30 |
| 20210403554 | METHODS FOR REDUCTION OF PATHOLOGICAL FIBROSIS AND ASSOCIATED DISORDERS AND DISEASES - Agents and methods for treating, reducing or ameliorating pathological fibrosis and disease or disorders caused by or associated with excessive deposition of fibrous tissue, and methods of identifying suitable agents. Preferred agents modulate the level and/or activity of GPR124. | 2021-12-30 |
| 20210403555 | ANTI-PODOPLANIN ANTIBODY - The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof. | 2021-12-30 |
| 20210403556 | Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders - Dosage regimens, methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease. | 2021-12-30 |
| 20210403557 | DOSING REGIMEN OF ANTI-TIGIT ANTIBODY FOR TREATMENT OF CANCER - The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody. | 2021-12-30 |
| 20210403558 | ANTI-TIM-3 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-TIM-3 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-TIM-3 ANTIBODIES - Provided herein are antibodies that selectively bind to Tim-3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods. | 2021-12-30 |
| 20210403559 | USE OF SEMAPHORIN-4D BINDING MOLECULES FOR THE TREATMENT OF RETT SYNDROME - Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D). | 2021-12-30 |
| 20210403560 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 - Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed. | 2021-12-30 |
| 20210403561 | ANTI-TREM-1 ANTIBODIES AND USES THEREOF - Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases. | 2021-12-30 |
| 20210403562 | ANTIBODIES BINDING TO CD3 - The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease. | 2021-12-30 |
| 20210403563 | ANTI-VEGF-PD1 BISPECIFIC ANTIBODY WITH NOVEL STRUCTURE AND USE THEREOF - The disclosure relates to an anti-VEGF-PD1 bispecific antibody with a novel structure and a use thereof, which belongs to the technical field of molecular immunology. The CDR-H1 in the heavy chain variable region of the antibody is an amino acid sequence expressed by SEQ ID NO: 1, the CDR-H2 is an amino acid sequence expressed by SEQ ID NO: 2, the CDR-H3 is an amino acid sequence expressed by SEQ ID NO: 3, and the CDR-L in the light chain variable region of the antibody is an amino acid sequence expressed by SEQ ID NO:4. | 2021-12-30 |
| 20210403564 | ONCOLYTIC VIRUS EXPRESSING PD-1 BINDING PROTEIN AND APPLICATION OF ONCOLYTIC VIRUS - Provided is an oncolytic virus expressing a PD-1 binding protein, i.e., an oncolytic adenovirus comprising a fusion protein expressing a PD-1 single-chain antibody. | 2021-12-30 |
| 20210403565 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof - A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided. | 2021-12-30 |
| 20210403566 | IMMUNOGENIC ARGINASE 2 POLYPEPTIDES - The present invention relates to novel polypeptides, which are derived from Arginase2. The invention also concerns uses of the polypeptides and compositions comprising the polypeptides. | 2021-12-30 |
| 20210403567 | METHODS OF TREATING CERVICAL CANCER BY ADMINISTERING A PD-1 INHIBITOR - The present disclosure provides methods for treating, reducing the severity of, or inhibiting the growth of a tumor or improving overall survival in a cervical cancer patient, wherein the method includes selecting a patient with cervical cancer in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof such as cemiplimab or a bioequivalent thereof). In certain embodiments, the patient has recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. | 2021-12-30 |
| 20210403568 | BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION - This invention relates to pharmaceutical formulations of therapeutic monoclonal antibody drugs and pharmaceutically acceptable excipients and a novel therapeutic strategy for the treatment of lung cancers including metastatic NSCLC by administration of such formulations using a soft mist inhaler and/or nebulizer. The pharmaceutical formulations comprise (a) a therapeutic monoclonal antibody selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, and bevacizumab, (b) water, and (c) a buffer. The pharmaceutical formulations are delivered locally to the lungs by inhalation for treatment of cancer. | 2021-12-30 |
| 20210403569 | METHOD OF TREATING LUNG CANCER - This disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity. | 2021-12-30 |
